Eli Lilly Cuts Price of Weight Loss, Diabetes Drug Zepbound

The drugmaker is cutting prices of single-dose vials by around half, for self-pay for patients with an on-label prescription.

An Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, N. J., on March 5, 2021. Mike Segar/Reuters

Pharmaceutical giant Eli Lilly announced on Aug. 27 that it is selling its weight loss and diabetes drug Zepbound in single-dose vials at around half the cost of some of its original doses.

In a press release, Eli Lilly said the move is part of ongoing efforts to significantly boost drug supply amid heightened demand.